OpenURL Connection Search

Select item for more details and to access through your institution.

Effect of Environmental Factors on Nuclear Organization and Transformation of Human B Lymphocytes.
Published in:
Biochemistry (00062979), 2018, v. 83, n. 4, p. 402, doi. 10.1134/S0006297918040119
By:
- Sall, F. B.;
- Germini, D.;
- Kovina, A. P.;
- Ribrag, V.;
- Wiels, J.;
- Toure, A. O.;
- Iarovaia, O. V.;
- Lipinski, M.;
- Vassetzky, Y.
Publication type:
Article
Thrombotic microangiopathy: a new dose-limiting toxicity of high-dose sequential chemotherapy.
Published in:
Bone Marrow Transplantation, 2001, v. 27, n. 5, p. 531, doi. 10.1038/sj.bmt.1702812
By:
- Vantelon, J M;
- Munck, J N;
- Bourhis, J H;
- Pico, J L;
- Fadel, C;
- Ulusakarya, A;
- Carde, P;
- Fenaux, P;
- Ribrag, V
Publication type:
Article
Scoring system for the prediction of successful peripheral blood stem cell (PBSC) collection in non-Hodgkin’s lymphoma (NHL): application in clinical practice.
Published in:
Bone Marrow Transplantation, 2000, v. 25, n. 5, p. 495, doi. 10.1038/sj.bmt.1702201
By:
- Vantelon, J M;
- Koscielny, S;
- Brault, P;
- Bourhis, J H;
- Ribrag, V;
- Pico, J;
- Fenaux, P;
- Munck, J N
Publication type:
Article
VIP (etoposide, ifosfamide and cisplatinum) as a salvage intensification program in relapsed or refractory Hodgkin's disease.
Published in:
Bone Marrow Transplantation, 1998, v. 21, n. 10, p. 969, doi. 10.1038/sj.bmt.1701202
By:
- Ribrag, V.;
- Nasr, F.;
- Bouhris, J.H.;
- Bosq, J.;
- Brault, P.;
- Girinsky, T.;
- Cosset, J.M.;
- Munck, J.N.;
- Corti, C.;
- Decaudin, D.;
- Pico, J.L.;
- Hayat, M.;
- Carde, P.
Publication type:
Article
New cytotoxic agents and their combinations for the treatment of chemoresistant glioblastoma and mantle cell lymphoma.
Published in:
Biopolymers & Cell, 2015, p. 1
By:
- Avdieiev, S.;
- Gera, L.;
- Havrylyuk, D.;
- Hodges, R.;
- Lesyk, R.;
- Ribrag, V.;
- Vassetzky, Y.
Publication type:
Article
A search of new treatment modalities for mantle cell lymphoma and glioblastoma.
Published in:
2013
By:
- Avdieiev, S.;
- Gera, L.;
- Havrylyuk, D.;
- Hodges, R.;
- Lesyk, R.;
- Ribrag, V.;
- Vassetzky, Y.
Publication type:
Abstract
JAK2<sup>V617F</sup> negatively regulates p53 stabilization by enhancing MDM2 via La expression in myeloproliferative neoplasms.
Published in:
Oncogene, 2012, v. 31, n. 10, p. 1323, doi. 10.1038/onc.2011.313
By:
- Nakatake, M;
- Monte-Mor, B;
- Debili, N;
- Casadevall, N;
- Ribrag, V;
- Solary, E;
- Vainchenker, W;
- Plo, I
Publication type:
Article
Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx.
Published in:
2001
By:
- Ribrag, V;
- Hajj, M Ell;
- Janot, F;
- Girinsky, T;
- Domenge, C;
- Schwaab, G;
- Fenaux, P;
- Bosq, J;
- Ell Hajj, M
Publication type:
journal article
Multiple molecular mechanisms contribute to radiation sensitivity in mantle cell lymphoma.
Published in:
Oncogene, 2003, v. 22, n. 39, p. 5961, doi. 10.1038/sj.onc.1206826
By:
- M'kacher, R.;
- Bennaceur, A.;
- Farace, F.;
- Laugé, A.;
- Plassa, L. F.;
- Wittmer, E.;
- Dossou, J.;
- Violot, D.;
- Deutsch, E.;
- Bourhis, J.;
- Stoppa-Lyonnet, D.;
- Ribrag, V.;
- Carde, P.;
- Parmentier, C.;
- Bernheim, A.;
- Turhan, A. G.
Publication type:
Article
A phase I, dose-escalation study of the Eg5-inhibitor EMD 534085 in patients with advanced solid tumors or lymphoma.
Published in:
Investigational New Drugs, 2013, v. 31, n. 6, p. 1530, doi. 10.1007/s10637-013-0026-9
By:
- Hollebecque, A.;
- Deutsch, E.;
- Massard, C.;
- Gomez-Roca, C.;
- Bahleda, R.;
- Ribrag, V.;
- Bourgier, C.;
- Lazar, V.;
- Lacroix, L.;
- Gazzah, A.;
- Varga, A.;
- Baere, T.;
- Beier, F.;
- Kroesser, S.;
- Trang, K.;
- Zenke, F.;
- Klevesath, M.;
- Soria, Jean-Charles
Publication type:
Article
P13.14 Use of Foundation one CDx for molecular screening in patients with primary brain tumors: Gustave Roussy Experience.
Published in:
Neuro-Oncology, 2019, v. 21, p. iii65, doi. 10.1093/neuonc/noz126.235
By:
- Baldini, C;
- Boulfoul, W;
- Lacroix, L;
- Rouleau, E;
- Scoazec, J;
- Varga, A;
- Hollebecque, A;
- Ribrag, V;
- Soria, J;
- Massard, C
Publication type:
Article
Phase I study of high-dose topotecan with haematopoietic stem cell support in the treatment of ovarian carcinomas: the ITOV 01 protocol.
Published in:
Bone Marrow Transplantation, 2006, v. 37, n. 7, p. 669, doi. 10.1038/sj.bmt.1705310
By:
- Lotz, J.-P.;
- Pautier, P.;
- Selle, F.;
- Viens, P.;
- Fabbro, M.;
- Lokiec, F.;
- Viret, F.;
- Gligorov, J.;
- Gosse, B.;
- Provent, S.;
- Ribrag, V.;
- Micléa, J.-M.;
- Dosquet, C.;
- Goetschel, A.;
- Cailliot, C.;
- Lefèvre, G.;
- Genève, J.;
- Lhommé, C.
Publication type:
Article
Infections occurring following IL6 blockade for the management of cytokine release syndrome in onco-hematology patients.
Published in:
Cancer Chemotherapy & Pharmacology, 2023, v. 92, n. 3, p. 229, doi. 10.1007/s00280-023-04551-6
By:
- Valery, M.;
- Saleh, K.;
- Ecea, R.;
- Michot, J. M.;
- Ribrag, V.;
- Fizazi, K.;
- Hollebecque, A.;
- Lecesne, A.;
- Ponce, S.;
- Loriot, Y.;
- Champiat, S.;
- Baldini, C.;
- Sarkozy, C.;
- Castilla-Llorente, C.
Publication type:
Article
Phase II trial and prediction of response of single agent tipifarnib in patients with relapsed/refractory mantle cell lymphoma: a Groupe d'Etude des Lymphomes de l'Adulte trial.
Published in:
2010
By:
- Rolland D;
- Ribrag V;
- Haioun C;
- Ghesquieres H;
- Jardin F;
- Bouabdallah R;
- Franchi P;
- Briere J;
- De Kerviler E;
- Chassagne-Clement C;
- Raponi M;
- Houlgatte R;
- Jais JP;
- Thieblemont C;
- Rolland, Delphine;
- Ribrag, Vincent;
- Haioun, Corinne;
- Ghesquieres, Herve;
- Jardin, Fabrice;
- Bouabdallah, Reda
Publication type:
journal article
Differential association of calreticulin type 1 and type 2 mutations with myelofibrosis and essential thrombocytemia: relevance for disease evolution.
Published in:
Leukemia (08876924), 2015, v. 29, n. 1, p. 249, doi. 10.1038/leu.2014.270
By:
- Cabagnols, X;
- Defour, J P;
- Ugo, V;
- Ianotto, J C;
- Mossuz, P;
- Mondet, J;
- Girodon, F;
- Alexandre, J H;
- Mansier, O;
- Viallard, J F;
- Lippert, E;
- Murati, A;
- Mozziconacci, M J;
- Saussoy, P;
- Vekemans, M C;
- Knoops, L;
- Pasquier, F;
- Ribrag, V;
- Solary, E;
- Plo, I
Publication type:
Article
A role for reactive oxygen species in JAK2(V617F) myeloproliferative neoplasm progression.
Published in:
2013
By:
- Marty, C;
- Lacout, C;
- Droin, N;
- Le Couédic, J-P;
- Ribrag, V;
- Solary, E;
- Vainchenker, W;
- Villeval, J-L;
- Plo, I
Publication type:
Journal Article
A role for reactive oxygen species in JAK2<sup>V617F</sup> myeloproliferative neoplasm progression.
Published in:
Leukemia (08876924), 2013, v. 27, n. 11, p. 2187, doi. 10.1038/leu.2013.102
By:
- Marty, C;
- Lacout, C;
- Droin, N;
- Le Couédic, J-P;
- Ribrag, V;
- Solary, E;
- Vainchenker, W;
- Villeval, J-L;
- Plo, I
Publication type:
Article
High survival rate with the LMT-89 regimen in lymphoblastic lymphoma (LL), but not in T-cell acute lymphoblastic leukemia (T-ALL).
Published in:
Leukemia (08876924), 2006, v. 20, n. 5, p. 814, doi. 10.1038/sj.leu.2404156
By:
- Jabbour, E.;
- Koscielny, S.;
- Sebban, C.;
- Peslin, N.;
- Patte, C.;
- Gargi, T.;
- Biron, P.;
- Fermé, C.;
- Bourhis, J. H.;
- Vantelon, J. M.;
- Arnaud, P.;
- Ribrag, V.
Publication type:
Article
Prognostic value of GST-p expression in diffuse large B-cell lymphomas.
Published in:
Leukemia (08876924), 2003, v. 17, n. 5, p. 972, doi. 10.1038/sj.leu.2402930
By:
- Ribrag, V;
- Koscielny, S;
- Carpiuc, I;
- Cebotaru, C;
- Vande Walle, H;
- Talbot, M;
- Fenaux, P;
- Bosq, J
Publication type:
Article
Phase II trial of CPT-11 in myelodysplastic syndromes with excess of marrow blasts.
Published in:
2003
By:
- Ribrag, V;
- Suzan, F;
- Ravoet, C;
- Feremans, W;
- Guerci, A;
- Dreyfus, F;
- Damaj, G;
- Vantelon, J M;
- Bourhis, J H;
- Fenaux, P
Publication type:
journal article
PHASE 1 STUDY OF JNJ‐67856633, A FIRST‐IN‐HUMAN MALT1 INHIBITOR, IN RELAPSED/REFRACTORY (R/R) B‐CELL NON‐HODGKIN LYMPHOMA (B‐NHL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL).
Published in:
Hematological Oncology, 2023, v. 41, p. 131, doi. 10.1002/hon.3163_88
By:
- Hertzberg, M.;
- Kalac, M.;
- Cheah, C. Y.;
- Ribrag, V.;
- Abrisqueta, P.;
- Opat, S.;
- Bachy, E.;
- Ysebaert, L.;
- Qiu, L.;
- Yi, S.;
- Nishimura, N.;
- Lemech, C.;
- Bussolari, J.;
- Deng, C.;
- Lu, T.;
- Xiu, L.;
- Hemelryck, S. V.;
- Philippar, U.;
- Guo, Y.;
- Soete, V.
Publication type:
Article
Risks and benefits of phase 1 clinical trials for patients with relapsed or refractory lymphoma, from 2008 to 2023.
Published in:
Hematological Oncology, 2023, v. 41, p. 600, doi. 10.1002/hon.3164_449
By:
- Michot, J. M.;
- Guerra, M.;
- Quivoron, C.;
- Mahjoubi, L.;
- Alouani, E.;
- Ouali, K.;
- Parisi, C.;
- Danlos, F.;
- Goldschmidt, V.;
- Hénon, C.;
- Baldini, C.;
- Ponce, S.;
- Ribrag, V.
Publication type:
Article
A phase II, open‐label, multicenter study of capivasertib, a potent, oral pan‐AKT inhibitor, in patients with relapsed or refractory B‐cell non‐Hodgkin lymphoma (CAPITAL).
Published in:
Hematological Oncology, 2023, v. 41, p. 562, doi. 10.1002/hon.3164_421
By:
- Hodson, D.;
- Shouse, G.;
- Shin, H.;
- Salar, A.;
- Bobillo, S.;
- Ribrag, V.;
- Macpherson, N.;
- Cordoba, R.;
- Kim, J. S.;
- Radford, J.;
- Guidez, S.;
- Herrera, A. F.;
- Morchhauser, F.;
- Johnson, D.;
- Izuzquiza, M.;
- Sambamurthy, N.;
- Forcina, A.;
- Gorgun, G.;
- Chen, R.;
- Younes, A.
Publication type:
Article
AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 195, doi. 10.1002/hon.3163_126
By:
- Kim, W. S.;
- Shortt, J.;
- Zinzani, P. L.;
- Mikhaylova, N.;
- Marin‐Niebla, A.;
- Radeski, D.;
- Ribrag, V.;
- Domenech, E. Domingo;
- Sawas, A.;
- Alexis, K.;
- Emig, M.;
- Garcia, L.;
- Overesch, A.;
- Pietzko, K.;
- Horwitz, S.
Publication type:
Article
LISOCABTAGENE MARALEUCEL (LISO‐CEL) VERSUS STANDARD OF CARE (SOC) AS SECOND‐LINE THERAPY IN LARGE B‐CELL LYMPHOMA (TRANSFORM STUDY): SUBGROUP ANALYSES BY PRIOR THERAPY RESPONSE.
Published in:
Hematological Oncology, 2023, v. 41, p. 212, doi. 10.1002/hon.3163_138
By:
- Nastoupil, L. J.;
- Kamdar, M.;
- Chavez, J. C.;
- Ghesquieres, H.;
- Ghosh, M.;
- Holmes, H.;
- López‐Guillermo, A.;
- Martínez‐López, J.;
- Novak, U.;
- Ribrag, V.;
- Roddie, C.;
- Waller, E. K.;
- Feldman, T.;
- Rosenthal, A. C.;
- Sauter, C.;
- von Bonin, M.;
- Karmali, R.;
- Montheard, S.;
- Previtali, A.;
- Abramson, J.
Publication type:
Article
VERY LONG‐TERM FOLLOW‐UP OF RITUXIMAB MAINTENANCE IN YOUNG PATIENTS WITH MANTLE CELL LYMPHOMA INCLUDED IN THE LYMA TRIAL, A LYSA STUDY.
Published in:
Hematological Oncology, 2023, v. 41, p. 151, doi. 10.1002/hon.3163_100
By:
- Sarkozy, C.;
- Thieblemont, C.;
- Oberic, L.;
- Moreau, A.;
- Bouabdallah, K.;
- Damaj, G.;
- Gastine, T.;
- Ribrag, V.;
- Casasnovas, O.;
- Haioun, C.;
- Houot, R.;
- Jardin, F.;
- Van Den Neste, E.;
- Cheminant, M.;
- Morschhauser, F.;
- Callana, M.;
- Ghesquieres, H.;
- Gressin, R.;
- Hermine, O.;
- Le Gouill, S.
Publication type:
Article
HIGH‐RISK MANTLE CELL LYMPHOMA IN THE LYMA TRIAL: A LYSA STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.64_2880
By:
- Cheminant, M.;
- Burroni, B.;
- Le Bris, Y.;
- Chartier, L.;
- Oberic, L.;
- Ribrag, V.;
- Delfau, M.‐H.;
- Thieblemont, C.;
- Gressin, R.;
- Canioni, D.;
- Peyre, M.;
- Laurent, C.;
- Steimle, T.;
- Kaltenbach, S.;
- Asnafi, V.;
- Macintyre, E.;
- Callanan, M.;
- Le Gouill, S.;
- Hermine, O.
Publication type:
Article
PREDICTION OF RELAPSE BY STANDARDIZED IG‐BASED ALLEL‐SPECIFIC QPCR, DDPCR AND AMPLICON NGS FOR MRD MONITORING IN MANTLE CELL LYMPHOMA: A COMPARATIVE ANALYSIS BY THE EU‐MCL NETWORK.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.63_2880
By:
- Pott, C.;
- Macintyre, E.;
- Delfau, M.‐H.;
- Weiß, A.;
- Schilhabel, A.;
- Soehlbrand, A.;
- Kehden, B.;
- Darzentas, N.;
- Kotrova, M.;
- Schoen, F.;
- Ribrag, V.;
- Brueggemann, M.;
- Villarese, P.;
- Dreyling, M.;
- Hermine, O.;
- Kluin‐Nelemans, H.;
- Jiang, L.;
- Hoster, E.
Publication type:
Article
EARLY POSITRON EMISSION TOMOGRAPHY RESPONSE‐ADAPTED TREATMENT IN LOCALIZED DIFFUSE LARGE B‐CELL LYMPHOMA (AAIPI=0) : RESULTS OF THE PHASE 3 LYSA LNH 09‐1B TRIAL.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.5_2879
By:
- Bologna, S;
- Vander Borght, T;
- Briere, J;
- Ribrag, V;
- Damaj, G. L;
- Thieblemont, C;
- Feugier, P;
- Peyrade, F;
- Lebras, L;
- Coso, D;
- Sibon, D;
- Bonnet, C;
- Morschhauser, F;
- Ghesquieres, H;
- Becker, S;
- Olivier, P;
- Fabiani, B;
- Tilly, H;
- Haioun, C;
- Bastie, J. N
Publication type:
Article
CIRCULATING TUMOR DNA LOAD AND TOTAL METABOLIC TUMOR VOLUME IN DIFFUSE LARGE B CELL LYMPHOMA (DLBCL) PATIENTS TREATED BY R‐CHOP – FROM REMARC, A LYSA STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.3_2880
By:
- Bohers, E;
- Delfau‐Larue, M;
- Vercellino, L;
- Cottereau, A;
- Viennot, M;
- Viailly, P;
- Salles, G;
- Tilly, H;
- Damaj, G;
- Haioun, C;
- Ribrag, V;
- Morschhauser, F;
- Casasnovas, R;
- Nicolas‐Virelizier, E;
- Feugier, P;
- Bouabdallah, R;
- Cartron, G;
- Renaud, L;
- Chartier, L;
- Portugues, C
Publication type:
Article
CHARACTERISTICS OF PATIENTS ACHIEVING COMPLETE OR PARTIAL RESPONSE (CR/PR) WITH TAZEMETOSTAT (TAZ) IN WILD‐TYPE RELAPSED/REFRACTORY (R/R) FOLLICULAR LYMPHOMA (FL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.21_2880
By:
- Batlevi, C. L.;
- Salles, G.;
- Tilly, H.;
- Chaidos, A.;
- McKay, P.;
- Phillips, T.;
- Assouline, S.;
- Campbell, P.;
- Ribrag, V.;
- Damaj, G. Laurent;
- Dickinson, M.;
- Jurczak, W.;
- Kaźmierczak, M.;
- Opat, S.;
- Radford, J. R.;
- Schmitt, A.;
- Rajarethinam, A.;
- Shang, G.;
- Morschhauser, F.
Publication type:
Article
GENDER DISPARITIES IN QUALITY OF LIFE OF FRENCH PATIENTS ONE YEAR AFTER THE DIAGNOSIS OF LYMPHOMA. A LYSA STUDY.
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.192_2880
By:
- Paunescu, A.‐C.;
- Paget, J.;
- Bergman, C. Copie;
- Malak, S.;
- Le Gouill, S.;
- Ribrag, V.;
- Bouabdallah, K.;
- Sibon, D.;
- Rumpold, G.;
- Preau, M.;
- Mounier, N.;
- Haioun, C.;
- Jardin, F.;
- Besson, C.
Publication type:
Article
COASTAL: A PHASE 3 STUDY OF THE PI3Kδ INHIBITOR ZANDELISIB WITH RITUXIMAB (R) VERSUS IMMUNOCHEMOTHERAPY IN PATIENTS WITH RELAPSED INDOLENT NON‐HODGKIN’S LYMPHOMA (INHL)
Published in:
Hematological Oncology, 2021, v. 39, p. 1, doi. 10.1002/hon.174_2880
By:
- Jurczak, W.;
- Zinzani, P. L.;
- Cunningham, D.;
- Yavrom, S.;
- Huang, W.;
- Gorbatchevsky, I.;
- Ribrag, V.
Publication type:
Article
RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 117, doi. 10.1002/hon.77_2629
By:
- Delfau‐Larue, M.H.;
- Boulland, M.L.;
- Feugier, P.;
- Maisonneuve, H.;
- Casasnovas, O.;
- Haioun, C.;
- Pica, G.M.;
- Lamy de la Chapelle, T.;
- Ysebaert, L.;
- Tilly, H.;
- Eisenmann, J.C.;
- Le Gouil, S.;
- Ribrag, V.;
- Jardel, H.;
- Glaisner, S.;
- Cartron, G.;
- Salles, G.;
- Xerri, L.;
- Fest, T.;
- Morschhauser, F.
Publication type:
Article
EZH2 GAIN‐OF‐FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 192, doi. 10.1002/hon.6_2630
By:
- Okosun, J.;
- Bödör, C.;
- Batlevi, C.;
- Nagy, N.;
- Michot, J.;
- Schneider, T.;
- Alizadeh, H.;
- Simon, Z.;
- Vose, J.;
- Younes, A.;
- Ribrag, V.;
- Fitzgibbon, J.;
- Yang, J.;
- Agarwal, S.;
- Newberry, K.J.;
- Michaud, N.R.
Publication type:
Article
SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 517, doi. 10.1002/hon.203_2631
By:
- Palomba, M.L.;
- Cartron, G.;
- Popplewell, L.;
- Ribrag, V.;
- Westin, J.;
- Chitra, S.;
- Huw, L.;
- Newberry, K.;
- Raval, A.;
- Xu, J.;
- Morschhauser, F.
Publication type:
Article
A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES.
Published in:
Hematological Oncology, 2019, v. 37, p. 556, doi. 10.1002/hon.2_2632
By:
- Zelenetz, A.;
- Zinzani, P.;
- Buske, C.;
- Ribrag, V.;
- Cunningham, D.;
- Jurczak, W.;
- Abrisqueta, P.;
- Agajanian, R.;
- Chaudhry, A.;
- Kayyal, T.;
- Wood, J.;
- Llorin‐Sangalang, J.;
- Brown, J.
Publication type:
Article
HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R‐CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 49, doi. 10.1002/hon.19_2629
By:
- Cottereau, A.;
- Vercellino, L.;
- Casasnovas, O.;
- Tilly, H.;
- Feugier, P.;
- Fruchart, C.;
- Roulin, L.;
- Oberic, L.;
- Pica, G.;
- Ribrag, V.;
- Abraham, J.;
- Simon, M.;
- Gonzalez, H.;
- Bouabdallah, R.;
- Fitoussi, O.;
- Sebban, C.;
- Lopez, A.;
- Macro, M.;
- Sahnes, L.;
- Morschhauser, F.
Publication type:
Article
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 44, doi. 10.1002/hon.14_2629
By:
- Le Gouill, S.;
- Beldi‐Ferchiou, A.;
- Cacheux, V.;
- Salles, G.;
- Canioni, D.;
- Bodet‐Milin, C.;
- Alcantara, M.;
- Delwail, V.;
- Gastinne, T.;
- Thieblemont, C.;
- Maisonneuve, H.;
- Lamy de la Chapelle, T.;
- Oberic, l.;
- Bouabdallah, K.;
- Ribrag, V.;
- Delfau‐Larue, M.;
- Macintyre, E.;
- Hermine, O.
Publication type:
Article
INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 154, doi. 10.1002/hon.111_2629
By:
- Morschhauser, F.;
- Tilly, H.;
- Chaidos, A.;
- Phillips, T.;
- Ribrag, V.;
- Campbell, P.;
- Ghandi Laurent, D.;
- Jurczak, W.;
- McKay, P.;
- Opat, S.;
- Radford, J.;
- Rajarethinam, A.;
- Yang, J.;
- Howell, H.;
- Newberry, K.J.;
- Adib, D.;
- Salles, G.
Publication type:
Article
PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP.
Published in:
Hematological Oncology, 2019, v. 37, p. 296, doi. 10.1002/hon.106_2630
By:
- Zinzani, P.L.;
- Armand, P.;
- Ribrag, V.;
- Michot, J.;
- Kuruvilla, J.;
- Zhu, Y.;
- Farooqui, M.;
- Nahar, A.;
- Moskowitz, C.H.
Publication type:
Article
RITUXIMAB PLUS LENALIDOMIDE IS AS EFFECTIVE AS IMMUNOCHEMOTHERAPY IN THE ERADICATION OF MOLECULAR DISEASE IN UNTREATED FOLLICULAR LYMPHOMA: RELEVANCE LYSA ANCILLARY STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 117, doi. 10.1002/hon.77_2629
By:
- Delfau‐Larue, M.H.;
- Boulland, M.L.;
- Feugier, P.;
- Maisonneuve, H.;
- Casasnovas, O.;
- Haioun, C.;
- Pica, G.M.;
- Lamy de la Chapelle, T.;
- Ysebaert, L.;
- Tilly, H.;
- Eisenmann, J.C.;
- Le Gouil, S.;
- Ribrag, V.;
- Jardel, H.;
- Glaisner, S.;
- Cartron, G.;
- Salles, G.;
- Xerri, L.;
- Fest, T.;
- Morschhauser, F.
Publication type:
Article
EZH2 GAIN‐OF‐FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS.
Published in:
Hematological Oncology, 2019, v. 37, p. 192, doi. 10.1002/hon.6_2630
By:
- Okosun, J.;
- Bödör, C.;
- Batlevi, C.;
- Nagy, N.;
- Michot, J.;
- Schneider, T.;
- Alizadeh, H.;
- Simon, Z.;
- Vose, J.;
- Younes, A.;
- Ribrag, V.;
- Fitzgibbon, J.;
- Yang, J.;
- Agarwal, S.;
- Newberry, K.J.;
- Michaud, N.R.
Publication type:
Article
SAFETY AND CLINICAL ACTIVITY OF ATEZOLIZUMAB IN COMBINATION WITH TAZEMETOSTAT IN RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA: PRIMARY ANALYSIS OF A PHASE 1B STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 517, doi. 10.1002/hon.203_2631
By:
- Palomba, M.L.;
- Cartron, G.;
- Popplewell, L.;
- Ribrag, V.;
- Westin, J.;
- Chitra, S.;
- Huw, L.;
- Newberry, K.;
- Raval, A.;
- Xu, J.;
- Morschhauser, F.
Publication type:
Article
OBINUTUZUMAB PLUS DHAP FOLLOWED BY AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) PLUS OBINUTUZUMAB MAINTENANCE PROVIDES A HIGH MRD RESPONSE RATE IN UNTREATED MCL PATIENTS. RESULTS OF LYMA‐101 TRIAL, A LYSA GROUP STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 44, doi. 10.1002/hon.14_2629
By:
- Le Gouill, S.;
- Beldi‐Ferchiou, A.;
- Cacheux, V.;
- Salles, G.;
- Canioni, D.;
- Bodet‐Milin, C.;
- Alcantara, M.;
- Delwail, V.;
- Gastinne, T.;
- Thieblemont, C.;
- Maisonneuve, H.;
- Lamy de la Chapelle, T.;
- Oberic, l.;
- Bouabdallah, K.;
- Ribrag, V.;
- Delfau‐Larue, M.;
- Macintyre, E.;
- Hermine, O.
Publication type:
Article
A PIVOTAL, RANDOMIZED, DOUBLE‐BLIND, PLACEBO‐CONTROLLED, TWO‐ARM, PHASE 2 STUDY OF ME‐401 INVESTIGATING TWO DOSING SCHEDULES IN PATIENTS WITH FOLLICULAR LYMPHOMA (FL) AFTER FAILURE OF TWO OR MORE PRIOR SYSTEMIC THERAPIES.
Published in:
Hematological Oncology, 2019, v. 37, p. 556, doi. 10.1002/hon.2_2632
By:
- Zelenetz, A.;
- Zinzani, P.;
- Buske, C.;
- Ribrag, V.;
- Cunningham, D.;
- Jurczak, W.;
- Abrisqueta, P.;
- Agajanian, R.;
- Chaudhry, A.;
- Kayyal, T.;
- Wood, J.;
- Llorin‐Sangalang, J.;
- Brown, J.
Publication type:
Article
HIGH TOTAL METABOLIC TUMOR VOLUME AT BASELINE ALLOWS TO DISCRIMINATE FOR SURVIVAL PATIENTS IN RESPONSE AFTER R‐CHOP: AN ANCILLARY ANALYSIS OF THE REMARC STUDY.
Published in:
Hematological Oncology, 2019, v. 37, p. 49, doi. 10.1002/hon.19_2629
By:
- Cottereau, A.;
- Vercellino, L.;
- Casasnovas, O.;
- Tilly, H.;
- Feugier, P.;
- Fruchart, C.;
- Roulin, L.;
- Oberic, L.;
- Pica, G.;
- Ribrag, V.;
- Abraham, J.;
- Simon, M.;
- Gonzalez, H.;
- Bouabdallah, R.;
- Fitoussi, O.;
- Sebban, C.;
- Lopez, A.;
- Macro, M.;
- Sahnes, L.;
- Morschhauser, F.
Publication type:
Article
PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP.
Published in:
Hematological Oncology, 2019, v. 37, p. 296, doi. 10.1002/hon.106_2630
By:
- Zinzani, P.L.;
- Armand, P.;
- Ribrag, V.;
- Michot, J.;
- Kuruvilla, J.;
- Zhu, Y.;
- Farooqui, M.;
- Nahar, A.;
- Moskowitz, C.H.
Publication type:
Article
INTERIM UPDATE FROM A PHASE 2 MULTICENTER STUDY OF TAZEMETOSTAT, AN EZH2 INHIBITOR, IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA.
Published in:
Hematological Oncology, 2019, v. 37, p. 154, doi. 10.1002/hon.111_2629
By:
- Morschhauser, F.;
- Tilly, H.;
- Chaidos, A.;
- Phillips, T.;
- Ribrag, V.;
- Campbell, P.;
- Ghandi Laurent, D.;
- Jurczak, W.;
- McKay, P.;
- Opat, S.;
- Radford, J.;
- Rajarethinam, A.;
- Yang, J.;
- Howell, H.;
- Newberry, K.J.;
- Adib, D.;
- Salles, G.
Publication type:
Article
PRELIMINARY EVIDENCE OF A MOLECULAR PREDICTOR OF TAZEMETOSTAT RESPONSE, BEYOND EZH2 MUTATION, IN NHL PATIENTS VIA CHARACTERIZATION OF ARCHIVE TUMOR AND CIRCULATING TUMOR DNA.
Published in:
Hematological Oncology, 2017, v. 35, p. 159, doi. 10.1002/hon.2438_14
By:
- Blakemore, S.J.;
- Daigle, S.R.;
- McDonald, A.A.;
- Morschhauser, F.;
- Ribrag, V.;
- Salles, G.;
- McKay, P.;
- Tilly, H.;
- Schmitt, A.;
- Le Gouill, S.;
- Fruchart, C.;
- Radford, J.;
- Zinzani, P.L.;
- Assouline, S.;
- Cartron, G.;
- Dickinson, M.;
- Morin, R.;
- Wu, H.;
- Sausen, M.;
- Clawson, A.
Publication type:
Article

Found: 63